BLISSGVS

Jan 21 (Reuters) - Bliss GVS Pharma Ltd BLIS.NS:

• TO CONSIDER ISSUANCE OF SWEAT EQUITY SHARES

Source text: ID:nBSE7zTS7Z

Further company coverage: BLIS.NS

(([email protected];;))

July 24 (Reuters) - Bliss GVS Pharma Ltd BLIS.NS:

• BLISS GVS PHARMA JUNE-QUARTER CONSOL NET PROFIT 207 MILLION RUPEES

• BLISS GVS PHARMA JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 1.84 BILLION RUPEES

Source text for Eikon: ID:nBSE2Py5qt

Further company coverage: BLIS.NS

(([email protected];))

Feb 16 (Reuters) - Bliss GVS Pharma Ltd BLIS.NS:

• APPROVED AN INTERNAL RESTRUCTURING OF FOREIGN SUBSIDIARIES OF COMPANY

Source text for Eikon: ID:nBSE2BQhKM

Further company coverage: BLIS.NS

(([email protected];;))

Sept 7 (Reuters) - Bliss GVS Pharma Ltd BLIS.NS:

• ASSISTANT COMMISSION OF STATE TAX MAHARASHTRA INITIATED SEARCH ON SEPT 6 AT CERTAIN PREMISES OF CO

• NO IMPACT ON OPERATIONS, OR ANY OTHER ACTIVITIES OF CO EXPECTED AS OF NOW

Source text for Eikon: ID:nBSEqz51y

Further company coverage: BLIS.NS

(([email protected];;))

** Shares of Indian drugmaker Bliss GVS Pharma BLIS.NS fall as much as 6.87% to 91.55 rupees in sharpest intraday slide since May 12

** Co posted more than 43% slide in consol net profit at 146.9 mln rupees ($1.78 million) for the quarter ended June 30, while rev slipped more than 11% to 1.60 bln rupees

** Stock on track for fourth consecutive session of losses

** More than 400,00 shares changed hands by 10:09 a.m. IST, 0.8X 30-day avg

** BLIS has risen 28% so far this year

($1 = 82.4425 Indian rupees)

(Reporting by Hritam Mukherjee in Bengaluru)

(([email protected];))

Aug 1 (Reuters) - Bliss GVS Pharma Ltd BLIS.NS:

• INDIA'S BLISS GVS PHARMA JUNE-QUARTER CONSOL NET PROFIT 146.9 MILLION RUPEES VERSUS PROFIT 257.2 MILLION RUPEES

• BLISS GVS PHARMA JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 1.6 BILLION RUPEES VERSUS 1.89 BILLION RUPEES

Source text for Eikon: ID:nBSEjtHVV

Further company coverage: BLIS.NS

(([email protected];;))

** Shares of Bliss GVS Pharma BLIS.NS rise as much as 4.01% to 83.05 rupees, their highest level since May 11

** Co receives establishment inspection report from U.S. FDA indicating closure of inspection at its manufacturing facility in Maharashtra nFWN3863JQ

** U.S. drug regulator assigns classification of "voluntary active indicated" for the facility

** Stock's trading volume at around 647,000 shares as of 3:02 p.m. IST, nearly thrice the 30-day avg - Refinitiv data

** BLIS has risen over 10% in 2023 so far compared to 3% gains in pharma index .NIPHARM

(Reporting by Bharath Rajeswaran in Bengaluru)

(([email protected]; +91 9769003463;))